ACC: COVID-19 Vaccination Cuts Risk for Cardiac Events With SARS-CoV-2 Infection

TUESDAY, March 7, 2023 (HealthDay News) -- Partial or complete COVID-19 vaccination is associated with a lower risk for major adverse cardiac events (MACE) after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, according to a research letter published in the March 7 issue of the Journal of the American College of Cardiology to coincide with the annual meeting of the American College of Cardiology, held from March 4 to 6 in New Orleans.

Joy Jiang, of the Icahn School of Medicine at Mount Sinai in New York City, and colleagues examined the association between vaccination and MACE among patients with prior SARS-CoV-2 infection. The analysis included 1.93 million patients identified from the National COVID Cohort Collaborative.

The researchers found that of the 13,948 patients experiencing MACE, most events occurred in the 12,733 nonvaccinated patients, while 160 events occurred in partially vaccinated patients and 1,055 occurred in fully vaccinated patients. The median time to MACE from index infection was 17 days. Comorbidities significantly differed in patients with and without MACE, including previous MACE (29.1 versus 0.9 percent), type 2 diabetes (33.9 versus 7.5 percent), hyperlipidemia (50.7 versus 14.4 percent), ischemic heart disease (40.6 versus 3.9 percent), liver disease (4.0 versus 0.8 percent), and obesity (29.4 versus 16.4 percent). Full (adjusted hazard ratio, 0.59) and partial vaccination (adjusted hazard ratio, 0.76) were associated with a reduced risk for MACE. Male sex, age (notably 66 years and older), and comorbidities (notably previous MACE) were associated with a significantly increased risk for MACE.

"To our surprise, even partial vaccination was associated with lower risk of adverse cardiovascular events," Jiang said in a statement. "Given the magnitude of SARS-CoV-2 infection worldwide, we hope our findings could help improve vaccination rates, especially in individuals with coexisting conditions."

Several authors disclosed financial ties to the biopharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

More Information